key: cord-0914348-0ftgh9z7 authors: Choi, Eun Young; Park, Hee Ho; Kim, Hyelim; Kim, Hong Nam; Kim, Inyoung; Jeon, Soyoung; Kim, Wantae; Bae, Jong-Sup; Lee, Wonhwa title: Wnt5a and Wnt11 as acute respiratory distress syndrome biomarkers for SARS-CoV-2 patients date: 2020-08-28 journal: Eur Respir J DOI: 10.1183/13993003.01531-2020 sha: 322e4d974c92df9242d42ce5a690d1dc1681e66e doc_id: 914348 cord_uid: 0ftgh9z7 Wnt5a/Wnt11 as ARDS biomarker for SARS-CoV-2 patients The coronavirus disease-19 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has spread globally, thereby resulting in declaration of pandemic emergency [1] . COVID-19 patients suffer from various infectious symptoms, including pneumonia, acute respiratory distress syndrome (ARDS) and sepsis. Some known-antiviral drugs, including remdesivir, have been proposed as effective agents for the treatment of SARS-CoV-2 infection [2, 3] . Along with the development of potential therapeutics, there is also urgency to mitigate the transmission and economic crisis of SARS-CoV-2 via identification of biomarkers that can rapidly indicate the severity of the disease in infected patients. Wnt ligands are secreted glycoproteins and their downstream signalling plays a pivotal role in embryonic development and tissue homeostasis. With remarkable progress in the immunology field, Wnt signalling has gained much attention as a critical regulator in various inflammatory diseases. A large body of evidence has suggested that Wnt ligands were secreted by immune cells, such as PBMCs, and non-immune cells, including stroma cell, to regulate inflammatory response and immune cell modulation [4] [5] [6] [7] . In addition to their roles in inflammation, recent studies have reported that these Wnt ligands play key roles in tissue damage and repair [6] . Interestingly, previous studies have reported significant alterations in Wnt5a and Wnt11 expression compared to other Wnt ligands by analyzing sera of patients with severe sepsis or sepsis mouse model [4, 8] . Wnt5a signaling has been known to activate in sepsis or ARDS and play a pivotal role in lung inflammation and fibrosis [5, 9] , whereas Wnt11 protein has been reported to suppress induction of inflammatory cytokines by regulating NF-κB activity [10, 11] . Previous reports have demonstrated that Wnt5a and Wnt11 have opposite functions to one another in response to inflammation [12, 13] ; hence it is thought that Wnt5a has pro-inflammatory effect and Wnt11 may be anti-inflammatory effect. Therefore, we focused on Wnt5a and Wnt11 to explore their potential relevance to COVID-19related diseases. In this study, we report Wnt5a and Wnt11 as reliable biomarkers for monitoring of pathological progression in SARS-CoV-2 patients. Heparinized blood samples were used fresh within 4 h, and peripheral blood mononuclear cells (PBMCs) were separated from blood using Ficoll-Hypaque or NycoPrep. Following this, more refined PBMCs were obtained via MACSprep™ PBMC Isolation Kit. To verify the effect of Wnt5a neutralizing antibodies or recombinant human Wnt11 on the suppression of cytokine secretion and NF-B activation, PBMCs isolated from SARS-CoV-2 patients were incubated with the Wnt5a antibody (20 g/ml) or recombinant human Wnt11 (10 ng/ml) for 6 hours. The supernatant was used for analysis of cytokines ELISA, and lysate was used for NF-κB activity analysis by an ELISA-based NF-κB family transcription factor assay kit (43296; Active Motif). All experiments were performed independently at least three times. Statistically significant differences were determined using unpaired t test. Prism software was used for statistical analyses. In order to establish reliable diagnostic biomarkers, we have conducted a prior study by exploring clinical manifestations and various risk factors on severe SARS-CoV-2 patients admitted to Yeungnam university medical center in Korea [14, 15] . We conducted research to discover new biomarkers in blood based on patient information such as age, BMI, and comorbidities ( Figure 1A ). The SARS-CoV-2 patient blood plasma samples were divided according to the severity of the disease; normal individuals (control group, tested for SARS-CoV-2 infection but negative), SARS-CoV-2 patients, SARS-CoV-2 patients with acute respiratory distress syndrome (SARS-CoV-2 ARDS), and discharged individuals after hospitalization by SARS-CoV-2 infection. ELISA analysis showed marginal difference in the Wnt5a secretion level between the SARS-CoV2 infection and the control group. Irrespectively, the Wnt5a protein level was dramatically increased in the blood of SARS-CoV-2 ARDS (Figure 1Ba) . Interestingly, the Wnt5a protein level was rescued in discharged individuals (Figure 1Ba ). This was consistent in the survived patients, where the Wnt5a level remained low in the plasma but significant high level of Wnt5a was still observed in the dead patients, thus demonstrating correlation of the Wnt5 level with the severity of the disease. (Figure 1Bb ). On the contrary, Wnt11 protein level was robustly induced in the plasma of SARS-CoV2 patients and discharged individuals, but remained at normal levels in SARS-CoV-2 ARDS, where the Wnt5a level was detected at its highest (Figure 1Bc-Bd) . To assess the regulation of Wnt5a and Wnt11 expression by SARS-CoV-2, peripheral blood mononuclear cells (PBMCs) were isolated from SARS-CoV-2, SARS-CoV-2 ARDS, and discharged patients. Based on transcriptional analysis by real-time qPCR (RT-qPCR), it was observed that the secretion in each plasma sample is associated with differential WNT5a and WNT11 mRNA expression level in the PBMCs (Figure 1Be However, treatment of rWnt11 to the PBMCs of SARS-CoV-2 ARDS showed dramatic inhibitory effect on NF-B activation as well as on cytokine production ( Figure 1Db-Dg) . These results suggest that Wnt11 protein has great efficacy in reducing inflammatory responses caused by SARS-CoV-2 infection, but Wnt5a is unlikely to be the potential therapeutic target. Previously, Wnt5a expression was upregulated by TGF-β, which induce pulmonary fibrosis [9] , and recent study has reported a significant increase of TGF-β in COVID-19 patent sera [16] . Thus, it is possible that elevation of Wnt5a in patient sera with severe COVID-19 may be due to TGF-mediated lung injury progression, whereby Wnt5a inhibition may not be effective in recovering of inflammatory responses. In summary, we investigated a single-centre and observational study in South Korea to identify biomarkers that could be used to monitor the progression and severity of the disease in the SARS-CoV-2 patients. By analysing plasma and PBMCs from patients with different pathological severities, our findings reveal that Wnt5a and Wnt11 show opposite expression pattern in SARS-CoV-2 ARDS patients. Based on our results, the measurement of Wnt5a level in SARS-CoV-2 ARDS patients may be a good indicator for poor prognosis, whereas Wnt11 levels may be a good indicator for ability to survive the disease. Given that Wnt11, not Wnt5a, efficiently inhibits inflammatory responses and cytokines production, it could be exploited as a therapeutic target for the treatment of SARS-CoV-2 ARDS patients. Asian Critical Care Clinical Trials G. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations Compassionate Use of Remdesivir for Patients with Severe Covid-19 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro WNT ligands contribute to the immune response during septic shock and amplify endotoxemia-driven inflammation in mice Early activation of pro-fibrotic WNT5A in sepsis-induced acute lung injury WNT signalling in the immune system: WNT is spreading its wings Canonical and Non-Canonical Wnt Signaling in Immune Cells Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10 Expression of WNT5A in Idiopathic Pulmonary Fibrosis and Its Control by TGF-beta and WNT7B in Human Lung Fibroblasts Wingless homolog Wnt11 suppresses bacterial invasion and inflammation in intestinal epithelial cells Gene Therapy with Adeno-associated Virus 9 Improves Recovery from Myocardial Infarction by Modulating the Inflammatory Response The Wnt5a-Ror2 axis promotes the signaling circuit between interleukin-12 and interferon-gamma in colitis Wnt-11 signaling leads to down-regulation of the AP-1 and NF-kappaB pathways and promotes viability in the CHO-K1 cells Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study Prognostic Factors for Severe Coronavirus Disease 2019 in Daegu Figure 1 Wnt5a/Wnt11: a promising diagnostic marker for SARS-CoV-2 ARDS. Plasma was secured from 20 healthy volunteers, 80 SARS-CoV-2 patients, 25 patients who progressed to ARDS (SARS-CoV-2 ARDS) and 25 discharged patients (No SARS-CoV-2 detected). (A) Baseline characteristics and clinical outcomes of COVID-19 patients admitted to Yeungnam University Hospital. (Ba-Bd) Analysis of Wnt5a and Wnt11 concentrations in SARS-CoV-2 patients. (Be-Bf) The mRNA expression of Wnt5a and Cb-Cc) Wnt5a or Wnt11 secreted from SARS-CoV-2, SARS-CoV-2 ARDS, and discharged patients were detected by ELISA. SARS-CoV-2 Sepsis patient plasma was incubated with Wnt5a antibody (20 g/ml) or recombinant human Wnt11 (10 ng/ml) for 6 h (each group n = 18). (Da) Binding activity of NF-κB (p65) in PBMC and (Db-Dg) plasma cytokines levels in SARS-CoV-2 ARDS patients PBMCs treated by anti-Wnt5a antibody-or recombinant human Wnt11 001 vs. Normal or Survival 001 vs SARS-CoV-2 05 vs. SARS-CoV-2 ## P<0.01 vs. SARS-CoV We thank the patients who participated in this study. None declared.